New study tracks long-term safety of IBD drug in kids
NCT ID NCT06405087
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others who did not respond well will be followed for up to 2 years. The goal is to track any side effects and see how the drug affects quality of life and hospital visits over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Juntendo University Hospital
RECRUITINGBunkyo-ku, Tokyo, 113-8431, Japan
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.